K. Wolski

New England Journal of Medicine · 2007–2020

A researcher in the Science corpus: 11 papers; trusts 0 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Who trusts K. Wolski overall

  1. D. Nathan
  2. S. Nissen
  3. Ralph DeFronzo
  4. Christian Weber
  5. John B. Buse

Papers from K. Wolski's perspective

Ordered by how strongly the researchers K. Wolski trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus (Annals of Internal Medicine)
  2. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
  3. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. (Journal of the American Medical Association (JAMA))
  4. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. (Journal of the American Medical Association (JAMA))
  5. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. (Journal of the American Medical Association (JAMA))
  6. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. (New England Journal of Medicine)
  7. Effect of torcetrapib on the progression of coronary atherosclerosis. (New England Journal of Medicine)
  8. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. (The Lancet)
  9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (Journal of the American College of Cardiology)
  10. Antiinflammatory Properties of HDL (Circulation Research)

Their papers